• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    12/2/24 4:17:10 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EGRX alert in real time by email
    false 0000827871 0000827871 2024-12-02 2024-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 2, 2024

     

    Eagle Pharmaceuticals, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware 001-36306 20-8179278
    (State or Other Jurisdiction (Commission File Number) (IRS Employer
    of Incorporation) Identification No.)

     

    50 Tice Boulevard, Suite 315
    Woodcliff Lake, NJ
      07677
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (201) 326-5300

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which registered
    Common Stock, $0.001 par value   EGRX   The Nasdaq Stock Market LLC(1)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     (1)On October 1, 2024, Eagle Pharmaceuticals, Inc. received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel had determined to delist the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq was suspended effective October 3, 2024. The Common Stock began trading on the OTC Expert Market on October 4, 2024 under the symbol “EGRX.”

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    The information set forth under “Item 3.03 Material Modification to Rights of Security Holders” of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    On December 2, 2024, Eagle Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as of October 30, 2024, by and between the Company and Equiniti Trust Company, LLC, as rights agent (as amended, the “Rights Agreement”).

     

    The Amendment makes certain technical amendments to the rights and obligations of the Board of Directors of the Company to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated by reference into this Item 3.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    4.1   Amendment No. 1, dated as of December 2, 2024, to Rights Agreement, dated as of October 30, 2024, by and between Eagle Pharmaceuticals, Inc. and Equiniti Trust Company, LLC, as rights agent.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          EAGLE PHARMACEUTICALS, INC.
           
    Dated: December 2, 2024 By: /s/ Michael Graves
          Michael Graves
    Interim Principal Executive Officer

     

     

     

    Get the next $EGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EGRX

    DatePrice TargetRatingAnalyst
    8/10/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    8/9/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    More analyst ratings

    $EGRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

      WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. ("Blue Owl") (the "Agreement"), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.   BENDEKA is a ready-to-dilute liquid, low-volume (50 mL) and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphoc

      3/31/25 4:00:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

      3/21/25 4:30:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

      WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that it has notified The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the "SEC") to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC. As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to

      11/15/24 5:00:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eagle Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

      8/10/23 7:32:29 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

      8/9/23 10:15:46 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts resumed coverage on Eagle Pharma with a new price target

      RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00

      4/7/21 6:39:38 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Financials

    Live finance-specific insights

    See more
    • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

      3/21/25 4:30:00 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

      WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

      10/31/24 8:00:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Delays Third Quarter 2023 Results and Conference Call

      WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

      11/9/23 7:30:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      11/14/24 11:34:47 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      11/5/24 4:32:23 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

      SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

      10/31/24 1:36:40 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

      WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

      11/12/24 7:00:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

      WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d

      7/18/22 6:50:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

      Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her

      5/3/21 6:50:00 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Krawtschuk Christopher

      3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      11/19/24 7:59:53 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tarriff Scott covered exercise/tax liability with 2,119 shares, decreasing direct ownership by 0.46% to 460,621 units (SEC Form 4)

      4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      3/1/24 4:40:02 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cahill Brian Joseph was granted 3,800 shares and covered exercise/tax liability with 1,589 shares, increasing direct ownership by 5% to 47,958 units (SEC Form 4)

      4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

      2/29/24 8:23:05 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EGRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eagle Pharmaceuticals Inc.

      15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      1/24/25 4:08:37 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Eagle Pharmaceuticals Inc.

      EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      12/10/24 12:15:03 AM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

      12/2/24 4:17:10 PM ET
      $EGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care